U.S. markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.84
    -2.50 (-2.65%)
     
  • Gold

    1,816.60
    +9.40 (+0.52%)
     
  • Silver

    20.78
    +0.43 (+2.12%)
     
  • EUR/USD

    1.0260
    -0.0066 (-0.64%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • GBP/USD

    1.2137
    -0.0066 (-0.54%)
     
  • USD/JPY

    133.4920
    +0.4930 (+0.37%)
     
  • BTC-USD

    24,106.42
    -71.44 (-0.30%)
     
  • CMC Crypto 200

    574.57
    +3.29 (+0.58%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Half-Year Report on the Liquidity Contract Signed by Lysogene With Kepler Cheuvreux

  • Oops!
    Something went wrong.
    Please try again later.
·11 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

PARIS, July 11, 2022--(BUSINESS WIRE)--Regulatory News:

Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today presents the half-year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux.

Under the liquidity contract concluded by LYSOGENE with the Kepler Cheuvreux brokerage firm, as of 30 June 2022, the following assets were held in the liquidity contract:

  • Number of shares: 114,809

  • Cash balance: € 60,656.15

  • Number of executions on buy side on the second half: 517

  • Number of executions on sell side on the second half: 395

  • Traded volume on buy side on semester: 239,253 shares for € 227,647.49

  • Traded volume on sell side on semester: 178,017 shares for € 178,988.67

As a reminder, as of 31 December 2021, the following assets were held in the liquidity contract:

  • Number of shares: 53,573

  • Cash balance: € 115,539.70

  • Number of executions on buy side on the second half: 224

  • Number of executions on sell side on the second half: 216

  • Traded volume on buy side on semester: 67,249 shares for € 142,998.52

  • Traded volume on sell side on semester: 57,255 shares for € 126,782.42

As a reminder, at the time of the implementation of the liquidity contract, the following assets were held in the liquidity contract:

  • Number of shares: 34,030

  • Cash balance: € 78,185.94

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June

22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

Buy Side

Sell Side

Number of
executions

Number of
shares

Traded volume in EUR

Number of
executions

Number of
shares

Traded volume in EUR

Total

517

239,253

227,647.49

395

178,017

172,988.67

03/01/2022

-

-

-

1

500

975.00

05/01/2022

1

500

975.00

2

1,000

1,990.00

06/01/2022

-

-

-

1

500

1,010.00

07/01/2022

7

500

975.00

-

-

-

10/01/2022

1

500

950.00

-

-

-

13/01/2022

6

2,000

3,660.00

1

500

950.00

14/01/2022

2

500

900.00

-

-

-

17/01/2022

1

500

925.00

4

1,001

1,881.88

18/01/2022

4

1,000

1,880.00

3

499

968.06

19/01/2022

1

500

925.00

-

-

-

20/01/2022

-

-

-

2

500

925.00

21/01/2022

3

1,000

1,810.00

-

-

-

24/01/2022

5

2,000

3,460.00

-

-

-

25/01/2022

3

500

840.00

-

-

-

26/01/2022

3

1,000

1,680.00

1

500

850.00

27/01/2022

5

1,000

1,650.00

1

500

850.00

28/01/2022

5

1,500

2,505.00

-

-

-

31/01/2022

1

500

810.00

-

-

-

01/02/2022

1

500

810.00

2

500

825.00

02/02/2022

3

1,177

1,883.20

-

-

-

03/02/2022

7

2,323

3,391.58

-

-

-

04/02/2022

1

500

700.00

3

1,000

1,480.00

07/02/2022

1

500

775.00

18

6,000

9,960.00

08/02/2022

6

2,000

3,120.00

1

500

825.00

09/02/2022

9

3,000

4,380.00

5

501

761.52

10/02/2022

-

-

-

10

3,999

6,318.42

11/02/2022

4

2,000

3,180.00

6

2,000

3,460.00

14/02/2022

19

8,000

11,520.00

-

-

-

15/02/2022

7

2,000

2,760.00

3

500

715.00

16/02/2022

-

-

-

3

500

705.00

17/02/2022

6

1,500

2,055.00

-

-

-

18/02/2022

5

1,500

2,025.00

1

500

690.00

21/02/2022

6

2,000

2,560.00

2

500

675.00

22/02/2022

3

1,500

1,770.00

-

-

-

23/02/2022

4

1,000

1,170.00

2

500

600.00

24/02/2022

5

1,500

1,650.00

12

5,620

7,025.00

25/02/2022

5

1,000

1,170.00

5

3,000

3,750.00

28/02/2022

-

-

-

6

1,500

1,815.00

01/03/2022

5

2,000

2,320.00

-

-

-

02/03/2022

2

1,000

1,100.00

-

-

-

03/03/2022

2

500

560.00

-

-

-

Buy Side

Sell Side

Number of
executions

Number of
shares

Traded volume in EUR

Number of
executions

Number of
shares

Traded volume in EUR

Total

517

239,253

227,647.49

395

178,017

172,988.67

04/03/2022

11

4,500

4,635.00

-

-

-

07/03/2022

4

1,500

1,365.00

-

-

-

08/03/2022

1

500

450.00

-

-

-

09/03/2022

-

-

-

5

3,500

3,605.00

11/03/2022

-

-

-

2

1,000

1,080.00

14/03/2022

2

1,000

1,100.00

4

2,500

2,800.00

15/03/2022

3

1,500

1,665.00

-

-

-

16/03/2022

12

4,000

4,600.00

26

8,000

9,520.00

17/03/2022

30

11,000

12,760.00

10

5,000

6,200.00

18/03/2022

14

6,000

6,240.00

1

500

565.00

21/03/2022

3

1,000

1,010.00

-

-

-

22/03/2022

6

1,500

1,515.00

5

383

390.66

23/03/2022

6

2,500

2,450.00

3

113

115.26

24/03/2022

2

1,000

960.00

3

1,387

1,400.87

25/03/2022

5

2,500

2,325.00

1

500

470.00

28/03/2022

8

3,500

3,220.00

4

2,000

1,900.00

29/03/2022

4

2,000

1,800.00

5

2,000

1,840.00

30/03/2022

8

4,000

3,400.00

1

500

450.00

31/03/2022

20

8,500

6,545.00

5

1,500

1,245.00

01/04/2022

7

3,501

2,765.79

5

2,632

2,105.60

04/04/2022

-

-

-

8

6,000

4,980.00

05/04/2022

8

3,000

2,490.00

3

2,000

1,720.00

06/04/2022

11

7,050

5,781.00

6

3,000

2,520.00

07/04/2022

-

-

-

4

2,000

1,660.00

08/04/2022

1

1

0.82

2

1,001

820.82

11/04/2022

2

1,950

1,579.50

1

10

8.20

12/04/2022

12

7,000

5,460.00

-

-

-

13/04/2022

15

10,000

8,200.00

37

18,000

16,020.00

14/04/2022

6

4,000

3,080.00

-

-

-

19/04/2022

-

-

-

3

1,000

780.00

20/04/2022

1

1

0.79

5

2,001

1,580.79

21/04/2022

7

5,000

4,000.00

16

10,000

8,400.00

22/04/2022

9

3,001

2,310.77

1

1

0.78

25/04/2022

2

1,000

750.00

1

1,000

770.00

26/04/2022

5

2,000

1,500.00

1

1,000

770.00

27/04/2022

3

1,500

1,125.00

-

-

-

29/04/2022

2

2,000

1,440.00

-

-

-

02/05/2022

3

3,000

2,100.00

1

100

71.00

03/05/2022

-

-

-

4

1,102

782.42

04/05/2022

-

-

-

1

798

582.54

05/05/2022

2

1,000

690.00

1

1

0.72

06/05/2022

4

1,435

990.15

3

2,999

2,129.29

09/05/2022

8

4,000

2,760.00

-

-

-

10/05/2022

8

6,000

3,960.00

-

-

-

11/05/2022

9

3,100

1,984.00

1

1,000

660.00

Buy Side

Sell Side

Number of
executions

Number of
shares

Traded volume in EUR

Number of
executions

Number of
shares

Traded volume in EUR

Total

517

239,253

227,647.49

395

178,017

172,988.67

12/05/2022

1

1,000

650.00

2

1,000

660.00

13/05/2022

-

-

-

4

2,000

1,360.00

16/05/2022

2

1,000

660.00

-

-

-

17/05/2022

-

-

-

7

4,840

3,388.00

18/05/2022

1

1,000

710.00

5

3,000

2,190.00

19/05/2022

4

2,029

1,400.01

-

-

-

20/05/2022

-

-

-

2

1,000

700.00

23/05/2022

2

2,000

1,380.00

3

2,000

1,400.00

24/05/2022

5

1,001

690.69

2

29

20.59

25/05/2022

3

2,001

1,380.69

2

973

690.83

26/05/2022

1

1

0.71

1

1

0.71

27/05/2022

2

1,000

690.00

1

350

248.50

30/05/2022

-

-

-

12

3,650

2,664.50

31/05/2022

1

1,000

750.00

4

4,000

3,080.00

01/06/2022

2

2,000

1,540.00

6

2,000

1,560.00

02/06/2022

1

1

0.77

5

1,253

964.81

03/06/2022

2

2,000

1,520.00

1

748

583.44

06/06/2022

7

4,000

3,120.00

23

13,500

11,340.00

07/06/2022

1

1

0.85

-

-

-

08/06/2022

15

10,742

8,486.18

-

-

-

09/06/2022

6

4,000

3,080.00

3

1,000

800.00

10/06/2022

3

3,000

2,190.00

-

-

-

13/06/2022

5

3,000

2,130.00

-

-

-

14/06/2022

8

5,000

3,350.00

1

22

15.62

15/06/2022

4

2,001

1,320.66

3

1,111

755.48

16/06/2022

9

7,000

4,410.00

1

903

614.04

17/06/2022

-

-

-

1

1,000

630.00

20/06/2022

2

1,000

630.00

5

4,000

2,640.00

21/06/2022

-

-

-

7

4,936

3,455.20

22/06/2022

1

1

0.70

7

2,001

1,400.70

23/06/2022

5

3,001

2,040.68

2

551

396.72

24/06/2022

2

150

102.00

4

2,000

1,400.00

27/06/2022

2

1,000

690.00

3

519

363.30

28/06/2022

-

-

-

2

482

337.40

29/06/2022

7

4,285

2,870.95

-

-

-

30/06/2022

-

-

-

2

2,000

1,380.00

About Lysogene

Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable a delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA and an adaptive clinical trial in GM1 gangliosidosis are ongoing. Lysogene has also entered into an exclusive worldwide license agreement with SATT Conectus for a gene therapy candidate for the treatment of the Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.

Forward Looking Statement

This press release may contain certain forward-looking statements, especially on the Company’s progress of its clinical trials and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs, (v) potential claims on its products, and (vi) a modification of the terms of its agreements with Sarepta Therapeutics. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "objective", "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2020 universal registration document, registered with the French Markets Authorities on April 12, 2021, under number D.21-0296, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005785/en/

Contacts

Stéphane Durant des Aulnois
Chief Financial Officer
stephane.durant-des-aulnois@lysogene.com
+ 33 1 41 43 03 99